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Abstract: The purpose of the study was to investigate placebo and buprenorphine effects on event-related potentials (ERPs) in
experimental pain and the potential benefit of population pharmacodynamic modelling in data analysis. Nineteen healthy volun-
teers received transdermal placebo and buprenorphine in a cross-over study. Drug plasma concentrations and ERPs after electrical
stimulation at the median nerve with intensity adjusted to pain detection threshold were recorded until 144 hrs after administra-
tion. Placebo and concentration-effect models were fitted to data using non-linear mixed-effects modelling implemented in NON-
MEM (V7.2.0.). Pharmacodynamic models were developed to adequately describe both placebo and buprenorphine ERP data.
Models predicted significant placebo effects, but did not predict significant effects related to buprenorphine concentration. Mod-
els revealed that ERPs varied both between subjects and between study occasions. ERPs were found to be reproducible within
subjects and occasions as population variance was found to be eight times higher than the unexplained variances. Between-sub-
ject variance accounted for more than 75% of the population variance. In conclusion, pharmacodynamic modelling was success-
fully implemented to allow for placebo and variability correction in ERP of experimental pain. Improved outcome of ERP
studies can be expected if variation between subjects and study occasions can be identified and described.
Opioids, such as buprenorphine, are widely used in clinical
pain management [1], but their usability is often limited by
intolerable side effects. Objective tools to improve evaluation
of both analgesia and side effects of analgesics are increas-
ingly desirable for clinical pain management and drug devel-
opment [1]. Several potential tools to evaluate effects of
analgesics have been described using experimental human pain
models, one of these being electroencephalography [2].
Electroencephalography reflects the electrical activity in the
brain with high temporal resolution. The activity may be
recorded as event-related potentials (ERPs) on the scalp during
repeated stimuli. The shape and timing of ERPs are dependent
on the stimulation site and type. Painful electrical stimulation
of the extremities in human beings gives rise to a characteris-
tic negative-positive potential in the ERP that can be measured
from the vertex position at the scalp [3]. The magnitude of
this potential, typically termed the vertex potential has most
often been quantified by the amplitude between the visually
identified peaks N2 and P2. Previous studies have shown that
this vertex potential correlates with the applied stimulus inten-
sity and has been suggested to correlate with pain intensity
[3,4]. These and other observations have frequently led to the
hypothesis that the vertex potential is produced by signals
mediated by the ascending nociception-specific Ad and/or
C-fibres [3]. ERPs may prove valuable in the assessment of
effects and side effects of analgesics. Electrically induced ver-
tex ERPs are relatively simple to perform, and they have often
been proposed to serve a role as a clinical tool to investigate
effects of analgesics [5]. Studies of opioids on vertex ERPs in
experimental pain have shown dose and concentration-depen-
dent reductions in ERP magnitude when fixed stimulus inten-
sity has been applied [4,6,7]. However, studies comparing
opioids and sedatives suggest that at least part of the opioid-
dependent reductions in ERPs are caused by sedation [8,9].
Furthermore, opioid-dependent latency shifts of N2 and P2
have been observed in one study [10], but this has not been
reproduced, and the significance of this is unclear.
A major hindrance in the study of ERPs in experimental pain
has been very large placebo effects and individual variations in
response. Pharmacodynamic non-linear mixed-effects modelling
is a technique that allows for mathematical descriptions of pla-
cebo effects and drug effects related to plasma concentration
and is applicable to studies of pain and analgesics, both across
the population and in the individual subjects [11,12]. This
allows for the description and explanation of the variability,
such as between-subject variabilities (BSV) and between-occa-
sion variabilities (BOV) that can be essential to the evaluation
of effects [13]. Despite the promising utility of the pharmacody-
namic modelling in the interpretation of analgesic effects on
ERPs, only one such study has been found in the literature [14].
However, this was done using a na€ıve pooled data approach that
did not take into account BSV, BOV or placebo effects.
Author for correspondence: Mads Kreilgaard, Department Drug Design
& Pharmacology, Faculty of Health & Medical Sciences, University of
Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark
(e-mail mads.kreilgaard@sund.ku.dk).
© 2014 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
Basic & Clinical Pharmacology & Toxicology, 2014, 115, 343–351 Doi: 10.1111/bcpt.12217
The hypothesis of this study was that population pharma-
codynamic modelling could be used as a tool to improve
data analysis of ERP data from experimental pain studies, by
accounting for several of the main limitations of traditional
ERP analysis. The primary aim was to describe a method to
develop pharmacodynamic models to investigate the nature
of placebo effects, the distributions of baseline and variations
in ERPs for an experimental study in which the applied
stimulus intensity was adjusted to achieve the same pain
(detection threshold). A secondary aim was to describe how
the developed model could be used for placebo-corrected and
distribution-normalized analysis of buprenorphine effects on
ERP.
Material and Methods
Study design. ERPs were recorded in a randomized, placebo-
controlled, cross-over study on 22 healthy male volunteers receiving
buprenorphine transdermally, in a dose used for clinical analgesia of
20 lg/hr for 144 hr, as previously described in detail [15]. A third
cross-over fentanyl treatment from the same study [15] was not
included as it was considered out of scope of the study to develop
two models of opioid effects on ERP. The study followed the tenets
of the Declaration of Helsinki promulgated in 1964 and was approved
by the local Ethical Committee (N-20070061) and the Danish
Medicines Agency (EduraCT number: 2007-004524-21), and informed
consent was obtained. Pharmacokinetic and pharmacodynamic
modelling of psychophysical assessments and different experimental
pain models for the study have been published in a complimentary
paper [15], and an advanced quantification method of ERP has been
published on data [16].
The study included 22 subjects, but two of the subjects dropped out
before second arm in the cross-over study. Both received buprenorphine
in the first arm. Subjects participated in 7 ERP sessions at pre-treatment
and at 4, 24, 28, 48, 72 and 144 hr after the start of treatment. In each
session, ERPs were recorded in two replicate runs with approximately
10-min. intervals. Blood samples were collected at pre-treatment, 6, 9,
12, 24, 36, 48, 60, 72, 78, 84, 96, 120, 144, 168, 192 and 216 hr and
analysed for plasma concentrations of buprenorphine and norbuprenor-
phine using ultra-pressure liquid chromatography followed by mass
spectrometry detection as previously reported [15].
ERPs were recorded after electrical stimulation of the median nerve.
Stimulation was applied at a constant level of pain (pain detection
threshold), as opposed to a fixed stimulus intensity as previously
reported by several studies [6–10]. This was done to ensure that the cor-
tical processes observed by ERP were actually related to pain. Variation
between ERP sessions and treatment with strong analgesic buprenor-
phine could otherwise lead to stimulation below pain level, which could
activate cortical processes very different from those that were aimed to
be studied.
Stimuli were applied by an electrical stimulator (Isolator Stimulator
Noxi IES 230, JNI Biomedical, Klarup, Denmark) through electrodes
placed on the skin. Stimulation was a 2 ms mono-polar square pulse
with 5-sec. inter-stimulus interval, and the stimulus intensity was
manually adjusted to individual pain detection threshold. The ERPs
were recorded with a sample rate of 1000 Hz using an EEG ampli-
fier (NuAmp, Neuroscan, El Paso, TX, USA) through a scalp elec-
trode at Cz (international 10–20 system) with a frontal electrode as
ground and an earlobe electrode as reference. The EEG amplifier
received trigger signals from the stimulator, and data were collected
on a computer. The recordings took place in a quiet, dim room with
all unnecessary equipment turned off to minimize extraneous influ-
ences on the ERPs.
ERPs were averaged using a notch filter at 49–51 Hz with
zero-phase-shift cut-off on 24 db/oct and were bandpass-filtered from 1
to 70 Hz with a zero-phase-shift filter with cut-off of 12 db/oct. Base-
line was adjusted to the mean of 100 to 0 ms. Sixty-three ERPs were
cleaned for artefacts by rejecting sweeps using EEG processing software
(Neuroscan software v 4.3, Compumedics, El Paso, TX, USA). Two
ERPs could not be cleaned adequately and were excluded on the justifi-
cation that they had absolute values over 200 lV [17].
Subjects were instructed in the use of a visual analogue scale and
instructed to identify the pain detection threshold (the minimum inten-
sity of a stimulus that is perceived as painful). Electrical stimulations
of the median nerve were applied at increasing intensities until pain
detection threshold was reached. ERPs were recorded at pain detection
threshold from 60 stimuli repetitions. This procedure was repeated in
a second run after approximately 10 min.
Data analysis. The pharmacodynamic parameters for placebo and
buprenorphine effects were estimated using non-linear mixed effects
modelling performed in the NONMEM software (Version 7.2.0) [18]
with the Wings for NONMEM interface (version 720; http://wfn.
sourceforge.net/). The R data analysis language (version 2.14.1) with
ggplot2 library was used for graphical output and data manipulation
[19]. The population approach was undertaken using the first-order
conditional estimation procedure with interaction (FOCE-I).
Pharmacodynamic models were developed in two steps. Firstly, a
placebo submodel was developed on placebo data only, and the
structure of the placebo submodels were then fixed in the
development of the drug-response models.
For five of seven ERP sessions, a time-matching blood sample was
collected, but for ERP sessions at 4 and 28 hr after dose (as well as
for missing blood samples), buprenorphine drug concentrations had to
be estimated for pharmacodynamic modelling. A cubic interpolating
spline, developed previously to describe buprenorphine concentrations
in the same data, was used to estimate concentrations, according to
the equation [15]:
YðtÞ ¼ k1 þ k2  t þ k3  t2 þ k4  t3
where Y is the concentration in the time interval between two
observed concentrations and coefficients(k14) were calculated for
each subject and time interval using the ‘spline’ package of the R lan-
guage. Splines were used rather than exponential functions as, the
time-course of buprenophine plasma concentrations were complex and
multi-peaked, confounding a description using standard compartment
models.
Quantification of ERP. Three different metrics were used to quantify
changes in the vertex potential of the ERPs.
Metric 1: PeakAmp. PeakAmp was defined and calculated as the
difference between the identified N2 and P2 amplitude of the vertex
potential. The subject mean N2 and P2 peaks were visually identified
on the average of all ERPs recorded for each subject. N2 amplitudes
were found by scanning a narrow interval of 50 ms around the
position of subject mean N2. P2 was found for all subjects by
scanning ERP for maximum value in the interval 150–300 ms.
Scanning was programmed in the TCL language in the software
Neuroscan. All identified peaks found by automatic scanning were
validated visually and corrected manually if necessary.
Metric 2: PeakLat. PeakLat was defined as the latency of the
identified N2 peak of the vertex potential. N2 latencies were found by
scanning a narrow interval of 50 ms around the position of subject
mean N2.
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Metric 3: MeanAmp. MeanAmp was defined and calculated as the
mean amplitude in the interval 116–152 ms. The MeanAmp metric, as
opposed to PeakAmp, did not require subjective assessment of peaks,
and was fully automated. The mean amplitude calculated in the
interval 116–152 ms have reported in a previous study of ERPs in
experimental pain electrically induced at the forearm [6], and thus
might be potentially translatable between studies.
Placebo models. The placebo structural model was investigated
among polynomials up to the 3rd order:
EPlacebo ¼ E0 þ h1  t þ h2  t2 þ h3  t3
where E0 was baseline effect, t was time after dose and h1–3
were estimable parameters [12]. 0th, 1st and 2nd order poly-
nomials were tested by eliminating terms as necessary.
A combination of additive and proportional residual error was
modelled. BSV was assessed to allow for interindividual variations
on baseline and slope parameters. BOV was modelled on baseline to
allow for different baselines between the treatment trials (1st or 2nd
visit in the cross-over design). Normality of data and random effect
distributions were assessed by Quantile–Quantile plots and distribu-
tion density plots. Box–Cox transformation was assessed on skewed
random effects. Discrete covariates were assessed on baseline of bi-
modal data. Variations due to age and weight were assessed as con-
tinuous covariates.
Buprenorphine response model. The buprenorphine structural models
were examined among linear, log-linear, Emax and sigmoidal Emax
models as has previously been characterizing opioid effects [15,20].
Both direct and indirect pharmacodynamic models were tested, with
indirect models having an effect compartment to describe any delays
between plasma concentration and effect:
dCe
dt
¼ ke0  ðCp  CeÞ
where Cp is the plasma concentration, Ce is the effect compartment
concentration and ke0 is the effect delay rate constant. For direct mod-
els Ce = Cp.
Linear drug model:
Edrug ¼ SLP  Ce
where SLP is the drug effect slope and Ce is the effect compartment
concentration.
Transformed log-linear drug model:
Edrug ¼ SLP  logðCe þ 1Þ
Addition of one to the concentration of the log-linear formula was
used to achieve a model that was centred around baseline (E0), and
the concentrations were converted to units that ensured the model to
remain log-linear in the relevant concentration interval.
Sigmoidal Emax model:
Edrug ¼ Emax  C
c
e
ECc50 þ Cce
where Emax is the maximum effect, EC50 is the concentration
needed to achieve half the maximum effect. Models were examined
both with and without the Hill coefficient c [20].
Model selection and evaluation. Models were selected based on
goodness of fit plots, residual and random effects distributions,
parameter estimate precision and Akaike Information Criterion (AIC)
[21,22]. A ΔAIC drop >2 was regarded as a critically better fit with
empirical support for a complex model over a simpler model, when
accounting for the number of parameters in the models. Two-hundred
bootstraps were performed for evaluation of model stability using the
Wings for NONMEM module (version 7) for NONMEM. Models were
evaluated using Visual Predictive Checks based on 500 simulations
performed in NONMEM and visualised using R.
Results
ERP recordings.
Of the 22 subjects who completed the study, three subjects
were excluded from further data analysis due to insufficient
signal to noise ratio, which prevented identification of the
peaks. Figure 1 shows the average of all recorded ERPs
(grand mean) for all included subjects with the visually identi-
fied peaks N2 and P2 of the vertex potential marked. The grey
area-under-the-curve shows the relative position of the interval
116–152 ms that has previously been used to quantify opioid
effects on ERPs after painful electrical stimulation of the fore-
arm [6].
Peaks N2 and P2 were identified on average ERPs for each
subject. Of the total number of ERPs for all time-points, 461
ERPs could be successfully identified by automatic scans in
intervals of 50 ms around N2 to obtain PeakAmp and PeakLat
data. For 13 ERPs, N2 was manually found within 25 ms of
the automatically scanned interval. For eight ERPs, no N2
peak could be manually identified, and these were excluded
from the PeakAmp and PeakLat data. MeanAmp was quanti-
fied for all ERPs. Figure 2 shows the relative position of
peaks identified for PeakAmp and PeakLat analysis to Mean-
Amp in three representative examples.
Pharmacodynamic modelling.
Throughout the study period, buprenorphine concentrations
were at least three times higher than the active metabolite
norbuprenorphine, and given that the intrinsic analgesic effect
of norbuprenorphine is one-fourth of buprenorphine in the rat
Fig. 1. Grand mean of all ERPs with denominations of the assumed
vertex potential peaks N2 and P2.
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[23], it was decided to limit the concentration-effect analysis
to buprenorphine.
PeakAmp model development.
The PeakAmp placebo data were best described by a 3rd
order polynomial model. A critically better fit (lower ΔAIC)
was obtained for the 3rd order polynomial compared with a
linear model (ΔAIC = 7.0) and a 2nd order polynomial
(ΔAIC = 2.6). BOV and Box-Cox transformed BSV were
implemented on baseline, and BSV was implemented on the
1st order slope. All BSVs, BOVs and Box-Cox models were
supported with improved ΔAIC and goodness of fit plots. A
systematic deviation was investigated between values recorded
for the two runs recorded at a 10-min. interval that constituted
an ERP session. A discrete covariate (CovRun) was imple-
mented to account for difference in baseline (E0) between the
first and second run. The implementation of CovRun on the
PeakAmp model was supported by ΔAIC = 26.1 and
improvements of goodness of fit plots. The PeakAmp drug
response was best described by an indirect transformed log-
linear model with BSV on the drug slope as seen in table 1.
The indirect model provided a critically better fit than a direct
model (ΔAIC = 29.1), and the log-linear model was better
than a linear (ΔAIC = 21.5). Emax models were not selected
despite critically better fits, as they proved unstable in boot-
straps with parameter relative standard errors (%S.E.) of
>1000%. The final PeakAmp model was evaluated using
goodness of fit plots, visual predictive checks and bootstraps.
Neither proportional nor additive error models could be omit-
ted without a critical increase in ΔAIC. No improved fits were
found when modelling age or weight as covariates on Peak-
Amp baseline or buprenorphine effects.
PeakLat model development.
The PeakLat placebo data were best described by a 2nd order
polynomial model with BOV and BSV on the baseline. A
critically better fit was obtained for this model compared with
a linear model (ΔAIC = 4.8), but 3rd order polynomials did
not improve fit further (ΔAIC = 1.3). A histogram of PeakLat
data (fig. 3) revealed that subjects could be divided into two
groups with distinct PeakLat distributions. A discrete covariate
(CovGroup) was implemented to allow for a different PeakLat
baselines (E0) between early and late groups. The appropriate-
ness of this covariate was supported by improvements in
ΔAIC and goodness of fit plots.
The PeakLat drug response to buprenorphine was best
described by a direct transformed log-linear model with BSV
on the drug slope as seen in table 1. The fit improved criti-
cally with a log-linear versus a linear model (ΔAIC = 8.6).
No indirect log-linear model converged successfully. As for
PeakAmp, Emax models were not selected due to parameter
instability.
The final PeakLat model was evaluated using goodness of
fit plots, visual predictive checks and bootstraps. Neither pro-
portional nor additive error models could be omitted without a
critical increase in ΔAIC. No age- or weight-related effects
were found on PeakLat.
MeanAmp model development.
The MeanAmp placebo data were best described by a 2nd
order polynomial model with BOV and Box-Cox transformed
BSV on baseline and BSV on the 1st order slope. Second
order models provided better fit than linear models
(ΔAIC = 14.7), but there was not a critically improved fit
with a 3rd order model (ΔAIC = 1.4). Similar to the Peak-
Amp model, a covariate (CovRun) was implemented on base-
line (E0) to account for difference between the first and
second runs in an ERP session with improved fit
(ΔAIC = 22.5) and goodness of fit plots.
The MeanAmp drug response was also best described by an
indirect transformed log-linear model with BSV on the drug
slope as seen in table 1. Log-linear models provided critically
better fits than linear models (ΔAIC = 15.3), and no indirect
log-linear model converged successfully. As for PeakAmp and
PeakLat, Emax models were not selected due to parameter
instability.
A B C
Fig. 2. Representative ERPs for three different subjects, recorded at baseline. (A) ERP with a clear negative–positive peak interpreted as the vertex
potential. (B) ERP with multiple negative peaks present at latencies below 150 ms, which complicated identification of N2. (C) ERP with multiple
overlapping negative peaks possibly responsible for producing a broad peak with shoulders around 120 ms. Automatically identified N2 and P2
peaks are plotted (white symbols). Mean amplitude in the interval 116–152 ms is plotted (grey symbols), with a grey band marking the interval
116–152 ms.
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The final MeanAmp model was evaluated using goodness
of fit plots, visual predictive checks and bootstraps. Neither
proportional nor additive error models could be omitted with-
out a critical increase in ΔAIC. No age- or weight-related
effects were found on MeanAmp.
Pharmacodynamic model predictions of effects on ERP.
PeakAmp, PeakLat and MeanAmp final models all conformed
to the model selection and validation criteria. Parameter esti-
mates and %S.E. for the final three pharmacodynamic models
are presented in table 1.
All models contained both BSV and BOV on baseline (E0).
The BSV as a proportion of the total variance of BSV + BOV
was calculated as 73.3% for PeakAmp, 85.0% for PeakLat
and 88.4% for MeanAmp.
Figure 4 shows the visual predictive checks for each model,
and fig. 5 shows the individual predicted versus observed
response.
All models included a logarithmic buprenorphine concentra-
tion-effect relationship with a BSV on the slope parameter.
Only PeakAmp converged successfully with a modelled effect
delay. For all models, the population mean effect slope had a
90% confidence interval including 0, as calculated from the
estimated %S.E. from NONMEM. This suggests that no popu-
lation drug effect (i.e. slope = 0) was a plausible description
of the data. The individual and population effects in the rele-
vant concentration interval are visualized in fig. 6.
Discussion
A robust procedure is described for development of non-linear
mixed effects models of placebo and drug effects on ERPs in
experimental pain using ΔAIC and goodness of fit plots and
visual predictive checks as model development criteria. Three
models were developed on different ERP metrics to adequately
Table 1.
Population parameter estimates and % standard error (%S.E.) produced by NONMEM of the three pharmacodynamic models. All population vari-
abilities (expressed as standard deviation x) were additive unless specified.
PeakAmp PeakLat MeanAmp
Units Estimate %S.E. Units Estimate %S.E. Units Estimate %S.E.
Placebo Model parameters
Baseline lV 24.9 18.2 ms 138 2.1 lV 5.43 25.6
h1 lV/hr 0.217 48.4 ms/hr 0.0622 49.7 lV/hr 0.0445 28.3
h2 lV/hr
2 0.00488 36.7 ms/hr2 0.000349 51.6 lV/hr2 0.000338 22.0
h3 lV/hr
3 0.0000221 36.7 – – – – – –
xBSV (baseline) lV 10.1 108.8 – 0.0763
1 32.4 lV 5.11 45.6
xBOV (baseline) lV 6.10 80.9 – 0.0321
1 37.4 lV 1.85 48.3
xBSV (slope1) lV/hr 0.158 181.7 – – – lV/hr 0.0136 44.5
CovRun – 0.855 2.7 – – – – 0.750 7.8
CovGroup – – – – 0.634 4.0 – – –
BoxCox – 0.0759 44.5 – – – – 0.108 29.6
Drug model parameters
Drug slope –2 0.501 115.0 –2 0.266 133.5 –2 0.211 61.6
Ke0 hr 0.442 85.5 – – – – – –
xBSV (Drug slope) – 1.45 49.3 – 1.136 35.8 – 0.473 51.8
RUV
eproportional % 8.82 98.1 % 3.30 66.9 % 9.20 55.2
eadditive lV 3.54 53.7 ms 3.46 106.7 lV 1.80 10.6
BSV, between-subject variability; BOV, between-occasion variability, RUV, residual unexplained variability; CovRun, Discrete covariate between
first and second ERP repetition, modelled on baseline; CovGroup, Discrete covariate between early and late peaks, modelled on baseline; BoxCox,
Box-Cox value, modelled on baseline BSV.
1Exponential BSV and BOV.
2Slope to the log of transformed buprenorphine concentration, which can be regarded as unitless.
Fig. 3. Histogram of PeakLat data. Relative density distributions is
grouped in subjects identified as having early N2 (white) and late N2
(gray).
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A B C
Fig. 4. Visual Predictive Checks for pharmacodynamic models (A) PeakAmp, (B) PeakLat and (C) MeanAmp. Visual Predictive Checks are shown
separately for placebo (top) and buprenorphine (bottom) data. Observed data is plotted with median (black lines) and 5th and 95th percentile
(dashed lines). The model predicted median (white lines) are shown along with the 90% prediction intervals (grey shade). Visual Predictive Checks
for PeakLat have been divided into two groups: early (white symbols) and late (gray symbols). This reflects the covariate implemented on baseline
to separate data with distinct distributions.
A B C
Fig. 5. Individual predicted versus observed response for (A) PeakAmp, (B) PeakLat and (C) MeanAmp. Response data are shown for placebo
(grey) and buprenorphine (white).
A B C
Fig. 6. Predicted buprenorphine effect for (A) PeakAmp, (B) PeakLat and (C) MeanAmp, when corrected for baseline and random errors. Individ-
ual predicted effects are marked with dashed lines. Population mean is shown (white line) with 90% confidence interval (grey band). The 90% con-
fidence interval around drug effect slope in all instances included zero.
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describe the time course of ERP data from both placebo and bu-
prenorphine arms of the study.
Impact of modelling placebo and baseline variability.
All structural developed placebo models were either polyno-
mial, quadratic (PeakLat and MeanAmp models) or cubic
(PeakAmp model) with individual variability (modelled as
BSV) in slopes. The placebo models indicate that ERPs
develop systematically over time, which may both be a natural
development over time and a direct result of placebo effects.
The developed placebo-model descriptions of placebo time-
course was considered a significant improvement with sub-
stantial empirical support compared with more simple models
(constant or linear), as based on the reduction in AIC
(ΔAIC < 10) [21]. This is considered empirical evidence that
conducting placebo-controlled cross-over studies is valuable in
experimental pain ERP studies. Failure to take into account
systematic changes in response over time have been reported
to lead to false conclusions about drug effects [12].
It was seen that baseline in measures related to amplitude
(both PeakAmp and MeanAmp) were not normally distributed
over individuals, but needed to be transformed using a box–cox
transformation for adequate description in the models. It was
evident that PeakLat data were not normally distributed, but
bi-modal in nature and that subjects could be separated into
two groups, one with early latency N2 and one with late latency
N2. Deviations to normality could have hampered data analysis,
but pharmacodynamic modelling allowed for covariates imple-
mentation and transformations to account for this. Furthermore,
the BOV model in all models described that significant (based
on ΔAIC) variability in ERP was present between first and sec-
ond treatment in the cross-over study. Together, these findings
add to understanding of the complexity of ERP data, but also
suggest that simplified data analysis not accounting for data
and variance distributions is suboptimal [6,9].
With non-linear mixed effects modelling as presented in this
paper, it was possible to develop placebo models that
accounted for the placebo and non-normal distributions as dis-
cussed. Assessed by visual predictive checks, the developed
placebo models provided adequate descriptive abilities of
baseline and placebo-time course to be suitable for placebo
correction in the analysis of buprenorphine effects.
Identification of variability sources to improve
pharmacodynamic models.
Large variability was observed in ERP data, as was expected
from descriptions of previous literature [4]. However, the
developed pharmacodynamic models revealed that the major
part of the variability could be explained as variation within
subjects or study occasion on baseline (modelled as BSV and
BOV). The combined (explained) variance of population
parameters on baseline (BSV + BOV) was in all metrics more
than 8 times higher than the combined variance of unex-
plained residual error (additive and proportional) when calcu-
lated at baseline mean levels. From the visual predictive
checks and random effects models, it was apparent that
variance was relatively constant over time. BSVs were in all
cases as large compared with BOVs as the BSV proportions
were calculated to be between 73–88% of the total population
parameter variance (BSV + BOV) on baseline for the three
models.
Together, these findings suggest that ERPs are relatively
reproducible especially within individuals, despite the large var-
iability in data. Improvements in the parameter estimation and
hence outcome of ERP studies can be expected if systematic
causes of variation between individuals or different study set-
tings can be identified and implemented as covariates. One such
covariate was found in this study, as a discrete covariate (Cov-
Run) was successfully implemented that described a significant
reduction in baseline of vertex potential amplitude (PeakAmp
and MeanAmp) between the first and the second of two repli-
cate run with approximately 10-min. interval. This reflected a
well-known phenomenon in ERPs described as habituation [7],
where the second of two ERPs conducted in a short interval has
reduced amplitude. Implementing this led to a reduction in ran-
dom effects and hence improved model strength.
The intensity of applied electrical stimulus is known to influ-
ence the ERP under various conditions [3,4], and would be
interesting to study as a covariate in the placebo models. How-
ever, the applied stimulus intensity was not available in this
study, and so the magnitude of any potential relationship
between this and ERP could not be investigated. In future stud-
ies of ERP with variable stimulus intensity, researchers are
encouraged to study the continuous effect of stimulus intensity
on ERPs. Potentially circadian rhythm may also affect the base-
line ERP response, and while this could not be investigated in
this study with only daily ERPs, it would be an interesting topic
for future studies. Also covariates due to demographic variation
might potentially improve models of ERP, but in this study,
subjects were homogenous regarding age, weight and height as
neither parameter explained any significant variations in base-
line, placebo or drug effects, when modelled as covariates.
Quantification of ERP and buprenorphine effect models.
PeakAmp and PeakLat quantified the amplitude and latency
of ERP vertex potentials in a procedure that resembled many
previous studies on opioid effects on ERP [7–9]. However, in
this study, it was found that a bi-modal distribution of subjects
was present based on the latency of the identified N2. It was
noted that for most subjects, there was a tendency towards
two distinct peaks around the expected latency of N2. It was
not in all cases possible to identify a minimum value for both
peaks, as they overlapped. This is consistent with previous
findings that electrical stimuli can result in multiple negative
peaks that are not necessarily related to the vertex potential
[3]. The bi-modal distribution might therefore signify that for
some subjects, a peak not related to the vertex potential might
have been quantified for PeakAmp and PeakLat. As an alter-
native to measure amplitude, the mean amplitude (MeanAmp)
was quantified in a specific interval as proposed by a previous
study where ERP was recorded after painful electricity was
applied to the forearm [6]. This quantification was simple to
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perform, did not require a minimum value in the selected
interval, did not require manual evaluation of the identification
and did not produce bi-modal distributions. It was found that
PeakAmp provided a less noisy metric than MeanAmp, as
both the additive error component relative to baseline as well
as the proportional error was lower for PeakAmp. This is in
line with the high signal-to-noise ratio of N2 to P2 peak to
peak amplitude, which is often presented as the rationale for
using this metric [3,4]. However, it was not possible to evalu-
ate which metric had the best relationship with magnitude of
the actual ERP vertex potential. More advanced quantification
methods could have been chosen [16], but the three simple
methods applied sufficed to demonstrate the impact of
accounting for placebo effects and baseline variation and sup-
port the use of pharmacodynamic modelling.
The models developed were in general consistent for all
three metrics used to analyse ERPs for effects in vertex poten-
tial amplitude and latency. Direct and indirect log-linear effect
models were selected based on empirical fit from a range
models, as no related models of buprenorphine effects on ERP
were found in the literature. Practical and ethical consider-
ations limited the pharmacodynamic sampling to seven ERP
sessions over 0–144 hr. These data did not allow stable fits of
advanced effect models such as sigmoidal Emax and biophase
models. This does not preclude that the actual relationship
between ERPs and opioids may be more advanced than the
direct or indirect log-linear relationship found in this study. It
is possible that more frequent sampling or sampling post-dos-
ing (beyond 144 hr) may have revealed more clear time-
dependent tendencies.
The lack of clear drug effects of buprenorphine on ERPs is
in contrast to both buprenorphine effects on other experimental
pain metrics [15] and opioid effects on the vertex potential
amplitude of ERPs in experimental pain [6–9]. This lack of
effect was not due to a subtherapeutic dosing of buprenorphine,
as the same dose in the same population showed significant
effect in models of bone-associated pain, heat pain, nerve
growth factor induced soreness and cold pressor pain models
[15]. However, it questions the usefulness of pain detection
threshold adjusted ERPs as a measure of opioids effects. Previ-
ous studies of opioid effects on ERPs [6–9] all used constant
stimulus intensities. In these studies, increased opioid concen-
tration has resulted in reduced pain intensity. However, in this
study, stimulus intensity was adjusted to achieve the same pain
(pain detection threshold), and hence increased buprenorphine
concentration did not lead to reduced pain, but will likely have
affected the stimulus intensity. Stimulus intensity was not
available for this study. However, the pharmacodynamic mod-
els developed and the methods described in this study provide
a framework for describing also variable stimulus intensity if
this is available from future trials.
Conclusion
This paper demonstrates the importance of correcting for
placebo effects and non-normal distributions in ERP data of
experimental pain. A robust method is presented for develop-
ing pharmacodynamic models that adequately described ERP
placebo and buprenorphine data for 19 healthy volunteers after
experimental stimulus of the median nerve at pain detection
threshold. It is concluded that population pharmacodynamic
modelling is a promising tool to identify sources of variability
when studying ERP in experimental pain. Future studies
should focus on identifying and describing variations in ERP
between individuals and study conditions.
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